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Abstract: Biopharmaceuticals are often produced by recombinant E. coli or mammalian cell lines. This is usually 
achieved by the introduction of a gene or cDNA coding for the protein of interest into a well-characterized strain of pro-
ducer cells. Naturally, each recombinant production system has its own unique advantages and disadvantages. This paper 
examines the current practices, developments, and future trends in the production of biopharmaceuticals. Platform tech-
nologies for rapid screening and analyses of biosystems are reviewed. Strategies to improve productivity via metabolic 
and integrated engineering are also highlighted. 
INTRODUCTION 
  Findings in the 1950s that DNA is the molecule that en-
codes proteins, which in turn control all the cellular proc-
esses inside the organism, have provided the impetus for the 
biotechnology era [1]. This has led to the advent of recombi-
nant DNA technology and hybridoma technology in the 
1970s, which marks the birth of modern biopharmaceutical 
development. As far as drug discovery and development is 
concerned, this is a significant milestone as some molecules 
are too complex and far too difficult to be extracted and puri-
fied from living materials, or synthesized chemically [2]. 
Genetic engineering provides an alternative means for the 
production of therapeutic proteins through the use of bacte-
ria, yeasts, insect, animal and plant cells. The compounds 
produced provide alternative therapies for serious life threat-
ening diseases such as cancer, viral infection or hereditary 
deficiencies, and other untreatable conditions [1]. 
  Various technologies have since emerged ranging from 
the innovations in broad-based, rapid screening and mac-
roscale analyses, to the sophistication in the imaging, control 
and automation technologies. Also contributing to the rapid 
progress are the innovations in gene therapies, antisense, cell 
surface engineering and molecular diagnostics. The produc-
tion of biopharmaceuticals via recombinant technologies has 
led to new, innovative products, as well as significant im-
provements in quality and yield of existing products. They 
are better defined scientifically, with consistent quality and 
are free from infectious agents due to stringent cGMP guide-
lines [2]. The industrial scale manufacturing of penicillin G 
by the fermentation of mould Penicillium  notatum in the 
early 1940s is the early success story of the use of living 
cells for drug production to combat infection by Staphylo-
coccus and other bacteria [3]. Since mid-1970s, large scale 
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production of hundreds of therapeutic proteins such as insu-
lin, monoclonal antibodies, interferons or interleukins, have 
been developed [1,2,4]. 
  The world wide pharmaceutical market is estimated to 
grow to $1.3 trillion by the year 2020 [5]. While chemical-
based drug continues to be the major source of drugs, the 
world-wide biopharmaceutical market in 2003 is estimated 
in the region of $30-35 billion, accounting for 15% of the 
overall world pharmaceutical market [6]. Of these, plant-
derived drugs and intermediates account for approximately 
$9-11 billion annually in the USA [2,5]. It was the scientific 
and technological innovation in drug discovery and devel-
opment that had led to the creation of hundreds of start-up 
biopharmaceutical companies in the 1970s and 80s. With the 
basic research done in the universities and research institu-
tions, the synergies between industrial players and academia 
over the years have resulted in the new technologies and 
tools to find new molecules to combat diseases; development 
of methods and biomarkers for clinical phenotyping; and 
validation of biochemical hypothesis of a drug candidate 
[1,2,4]. The growing confidence and interest in biopharma-
ceuticals has pushed big pharma companies to acquire tech-
nologies or invest in manufacturing facilities. Merck has 
bought RNAi developer, Sirna Therapeutics for $1.1 billion 
(RNAi being short interfering molecules to inhibit any gene 
of interest in any cells) [7]. Genentech has invested $140 
million to set-up microbial-based manufacturing operations 
for biotherapeutics in Asia [8]. Despite high expenses in 
R&D, Merck and Genentech earn $32.8 and $1.4 billion in 
revenue, respectively, in the year 2000 [4]. This review arti-
cle examines the practices, developments, and future trends 
in the production of biopharmaceuticals. 
HOST SYSTEMS FOR MOLECULAR PHARMING 
  The triggering factor behind the revolution in biopharma-
ceutical industries can largely be attributed to the develop-
ment of advanced methods in the field of recombinant DNA 50    The Open Medicinal Chemistry Journal, 2008, Volume 2  Abdullah et al. 
technology. Cell engineering and transgenic technology bor-
der on several enabling techniques in such diverse fields as 
cell biology, embryology, molecular genetics, bioprocesses 
and metabolic engineering. A more directed approach to 
improve the cells or a given pathway of interest have become 
possible with specific genetic perturbations through modifi-
cation of the promoter strength of a given gene, or by gene 
deletions, or by introducing whole new genes or pathways 
into the cells [9-12]. This means that the alteration effects 
can be determined and the amount directly-probed and pro-
duced at a specified quantity. 
  Scientific advances gained by transgenic capabilities also 
enable further understanding of basic biological pathways 
and yield insights into how changes in fundamental proc-
esses can perturb programmed development or culminate in 
disease pathogenesis [13]. Primary step behind recombinant 
DNA technology is the introduction of heterologous gene(s) 
in a non-native genetic background, and the sufficient ex-
pression of a cloned gene in the new host system. Two types 
of gene library are known, namely the genomic library which 
includes all the total chromosomal DNA of an organism; and 
cDNA library which corresponds to the mRNA fraction from 
a cell or tissue at specific point and time [14]. 
Recombinant Microorganisms 
  Biopharmaceuticals produced from microorganisms that 
have gained marketing approval are invariably produced in 
the recombinant E. coli cell systems such as E. coli K12. The 
species are well-studied, documented and optimized as hosts 
for gene cloning [15-17]. These biopharmaceutical products 
include tissue plasminogen activator, insulin, ,-interferons, 
interleukin-2, granulocyte colony stimulating factor and hu-
man growth hormone [1,2,18]. The advantages that are nor-
mally associated with E. coli as the source of biopharmaceu-
ticals include the well-characterized molecular biology and 
the ease of genetic manipulation; high levels of heterologous 
protein expression (as high as 25% of total cellular protein in 
the case of -interferon); relatively simple and inexpensive 
media, supported by well-established fermentation technol-
ogy [2]. 
  However, vast bulk of heterologous proteins from E. coli 
are intracellular which could complicate the downstream 
processing. There is also the possibility of the formation of a 
highly-densed inclusion body or insoluble aggregates of pro-
teins, which could overload the normal protein-folding 
mechanism. Being a gram negative bacteria, the presence of 
endotoxin molecule lipopolysaccharides (LPS) in E. coli is a 
concern [2,19]. LPS, which make up 75% of E. coli’s outer 
membrane surface, influence the hypothalamic regulation of 
body temperature when they enter the blood-stream, and 
cause fever, which in some instances fatal. E. coli also often 
does not recognize the upstream elements of genes derived 
from different bacterial genera or families, or in some cases 
the over expressed protein may be toxic. Yeast protein 
kinase over-expressed in E. coli for example has been found 
inactive, but the same protein is active when expressed in 
yeast [20]. It is therefore common to transfer a gene which is 
originally cloned in E. coli, back into its native genetic back-
ground such as the -amylase gene cloned in E. coli but 
transferred and expressed in its native Bacillus amylolique-
faciens, or antibiotic biosynthetic genes in Streptomycetes 
species [2]. 
  Many therapeutically useful proteins, when naturally 
produced in the body are glycosylated. The limitation in bio-
logical activities of some expressed proteins from prokaryo-
tes has been attributed to their limited capability to carry out 
post-translational modifications (PTMs) [2,21]. Vast major-
ity of therapeutic proteins undergo several PTMs, which are 
the final steps in which genetic information from a gene di-
rects the formation of a functional gene product. PTMs in-
clude covalent modifications of individual amino acids resi-
dues such as glycosylation, phosphorylation, methylation, 
ADP-ribosylation, oxidation and glycation; proteolytic proc-
essing and non-enzymatic modifications such as deamidation 
and racemisation. Most therapeutic proteins require at least 
proteolytic cleavages, oligomerization and glycosylation for 
their bioactivity, pharmacokinetics, stability and solubility 
[22,23]. Polyglutamylation is an example of PTM that
 gener-
ates lateral acidic side chains on proteins by sequential
 addi-
tion of glutamate amino acids. This modification is first
 dis-
covered on tubulins, and is important for several microtubule
 
functions [24]. As complex therapeutic proteins produced in 
prokaryotes are not always properly folded to confer the de-
sired biological activity, microbial expression system is suit-
able mainly for the expression of relatively simple proteins 
which do not require folding or PTMs to be biologically ac-
tive. Table 1 shows the comparison between different trans-
genic systems for the production of recombinant proteins. 
Eukaryotic Cell Systems 
  Major advantage of eukaryotic expression systems such 
as yeast, Chinese hamster ovary strain K1 (CHO-K1) or 
Baby hamster kidney cells (BHK), is their ability to carry out 
PTMs of protein product. While bacteria and yeasts may 
only be suitable for the synthesis of antibody fragments, in-
sect cells infected by baculovirus and CHO cells can be the 
source of intact antibodies. Animal cell cultures are being 
used for the production of monoclonal antibodies via hybri-
doma cell technology; and vaccines production such as yel-
low fever viral particles via chick embryos culture, hepatitis 
A viral vaccines via human diploid fibroblast or gp120 [2]. 
Fungi such as Aspergillus niger and yeast such as Pichia 
pastoris have received considerable attention due to their 
potential for high level of protein expression such as factor 
VIII, -interferon or Human Serum Albumin; and protein is 
excreted out into the extracellular media [25-27]. The gp160 
HIV vaccines for example have been produced not only in 
insect or CHO cell-lines, but also in Saccharomyces cere-
visiae [2]. Large scale production of polypeptides normally 
present on the surface of pathogen can now be produced by 
producer organisms such as hepatitis B surface antigen 
(HBsAg) genes expressed in yeast for the production of 
clinically-safe subunit vaccines [28]. 
  Yeast has received considerable attention due to its more 
detailed genetics and molecular biology that can facilitate 
genetic manipulation, and a long history of application in 
brewing and baking. It is thus considered as GRAS organism 
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for the use of yeast as host system is its ability to assemble 
DNA fragment in genomes by homologus recombination 
which allows the insertion of DNA sequences at specific 
locations in the yeast genome [31]. In the application of 
“biodrug” into the gastrointestinal tract, yeasts can be advan-
tageous over bacteria, for the functional expression of het-
erologous genes, and they are not sensitive to antibiotics 
with high level of resistance to digestive secretions [30,32]. 
A “biodrug” concept involves the use of recombinant micro-
organisms as new delivery vehicles which may have poten-
tial medical applications in the correction of enzyme defi-
ciencies, the control of the activation of pro-drug to drug or 
the production of therapeutic proteins, such as vaccines, di-
rectly in the digestive tract. The recombinant cells may pro-
duce active compounds such as hormones, enzymes, and 
vaccines; or perform bioconversions or “biodetoxication” 
[32,33]. 
  The eukaryotic cell-based system however may need a 
more complex nutritional requirement as compared to   
E. coli. It may also require a carefully controlled-fementation 
condition due to the shear sensitivity of the cells, and also to 
control protein glycosylation which may depend on cell me-
tabolism such as that in CHO [34]. Cell growth are much 
slower, the post-translational glycosylation pattern especially 
in yeast and fungal cells may be inappropriate or different 
from the pattern observed in native glycoprotein isolated 
from natural sources, and the cells are often proned to con-
tamination by virus or prions [2]. Scaling-up of cultured 
mammalian cells to large volumes is more difficult. It may 
take 4 years to build a 100000L fermenter, costing $400 mil-
lion for CHO cells [35]. Because of huge capital costs, in-
dustry has been unable to keep up with the growing demand 
[36]. Another method that can be explored is to extract bio-
pharmaceuticals from animal and human tissues such as in-
sulin from pig and cow pancreas, or blood proteins from 
human blood [37]. However, these also incur high-cost and 
carry the risk of transmitting infectious diseases to humans 
[38]. 
Transgenic Animal 
  The biochemical, technical and economic limitations of 
prokaryotic and eukaryotic expression systems have spurred 
interest in transgenic animal and plant as new expression 
systems. Transgenic animal as a bioreactor system for phar-
maceutical production, or for modification of tissues and 
organs for transplantations, or as a model system from DNA 
microinjection to gene targeting and cloning, has had a sig-
nificant impact on human health, pharmaceutical discovery 
and the drug pipeline [13]. Transgenic modifications, par-
ticularly in mice, are commonly used to model human condi-
tions. The use of transgenic animal have been beneficial in 
the studies for drug discovery in human developmental and 
pathological conditions, including gene therapy, genetic ba-
sis of human and animal disease, the assessment of the valid-
ity of therapeutic strategies before clinical trials, disease re-
sistance in humans and animals, drug and product testing or 
toxicological screening, and novel product development 
through molecular pharming [13,39]. 
  The production of therapeutic proteins from transgenic 
animals involves the expression from mammary-gland spe-
cific promoters to drive secretion of the transgene into milk, 
or the use of kidney- or bladder specific promoters that direct 
transgene expression to the urine [40-42]. Mammary specific 
expression is achieved by fusing the gene of interest with 
promoter containing regulatory sequences of a gene coding 
for a milk-specific protein, such as whey acid protein pro-
moter in the -casein and - -lactoglobulin genes [2]. The 
early success story of transgenic expression of a Human Tis-
sue-Type Plasminogen Activator (tPA) has been reported in 
mouse milk [43] and Goat Milk [44]. The European Medi-
Table 1.  Transgenic Systems for the Production of Biopharmaceuticals 
 
Bacteria  Mammalian  Transgenic Animal  Transgenic Plant 
1. Productivity 
g/L culture 
 
 
2. Advantages 
Easy to culture 
Well-characterised 
 
 
 
3. Limitations 
Lack of PTMs 
Limited capacity 
 
 
4. Issues 
Presence of inclusion bod-
ies, endotoxin molecules 
 
g/L culture 
 
 
 
PTMs mechanism 
 
 
 
 
 
Inappropriate PTMs 
More complex media 
Slow cell growth 
Limited capacity 
 
Viruses and prions contamination 
 
g/L milk or urine 
 
 
 
Low capital cost 
Easy to harvest 
Easy to scale-up 
PTMs mechanism 
 
 
Inconsistent product yield 
 
 
 
 
Methods for genetic modification 
 
kg/ha or 
g/L (for latex) 
 
 
Low cost 
Easy to harvest 
Easy to scale-up 
PTMs mechanism 
 
 
Low product yield 
Environmental concern on GMOs 
 
 
 
Need stronger promoters 
Targeted protein expression in spe-
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cines Agency (EMEA) has approved the use of ATryn, a 
drug extracted from the milk of goats engineered to carry a 
human gene involved in inhibiting blood clots [45]. For 
monoclonal antibodies, the vast majority of production 
source are of murine origin [2]. Major problems associated 
with murine antibodies include the reduced stimulation of 
cytotoxicity and the formation of complexes after repeated 
administration, resulting in mild allergic reactions and 
anaphylactic shock [46]. Rabbit milk is seen as an attractive 
alternative source for antibodies, as rabbit is not susceptible 
to prion diseases and is known to transmit only rare and mi-
nor diseases to human [47]. Other various end-organs and 
system being investigated for antibodies production include 
blood, urine and other tissues, and egg white from transgenic 
chicken. In 2002, a mature and functional human immuno-
globulins has been reported in the blood of transchro-
mosomic calf. This is achieved by introducing a human arti-
ficial chromosome (HAC) vector containing the entire unre-
arranged sequences of the human immunoglobulin (hIg) 
heavy-chain (H) and lambda () light-chain loci, into bovine 
primary fetal fibroblasts using a microcell-mediated chromo-
some transfer (MMCT) approach [48]. The use of the tran-
schromosomic calves is an important step in the develop-
ment of a system for producing therapeutic Human poly-
clonal antibodies (hPABs). 
  In the area of human xenotransplantation, the transgenic 
models remain a viable option in dealing with severe donor 
organ shortages. Research continues to address the biological 
barriers with regards to hyperacute rejection mediated by 
preformed natural antibodies and complement [13,49]. An 
important development in the area of xenotransplantation is 
the stem cell and nuclear transfer cloning procedures such as 
that being developed in the production of -1,3-
galactosyltransferase knockout pigs [50-52]. The embryonic 
stem-cell technology has moved from the well studied trans-
genic mouse to now include the transgenic fish, chicken, 
rabbits, sheep and cattle [53,54]. The main advantages of 
transgenic animal as a source of biopharmaceutical produc-
tion are as shown in Table 1. High protein expression level is 
achievable (in many cases exceeding 1 g protein/litre milk, 
which may be similar to 50-100 litre bioreactor in a day) [2]. 
There is less environmental concern as transgenic farm ani-
mals are kept in enclosed areas. The only drawback is the 
variability in the expression levels ranging from 1 mg/L to 1 
g/L. This can be improved through vector optimization and 
the use of gene insulators for increased and more predictable 
production such as for antibodies in milk [47,53]. 
Transgenic Plant 
  Both transgenic animal and plants may be the only tools 
capable of producing high level of protein or antibodies [47]. 
Different types of therapeutic proteins such as blood and 
plasma proteins, vaccines, hormones, cytokins and growth 
factors, enzymes and others such as hirudin, endostatin and 
human lactoferrin, have been produced in transgenic plant 
systems mainly in tobacco and potato [22]. Many antibodies 
or antibody fragments have been produced for therapeutic or 
diagnostic purposes in various plant expression systems [55]. 
These plant-based antibodies are correctly assembled, prote-
olytically matured and glycosylated, with high mannose and 
biantennary complex type N-glycans [56,57]. While animal 
and plant cells may have similar capacity to assemble anti-
body subunits, plants may differ from animals in carrying 
out PTMs, as far as the capacity to glycosylate antibodies is 
concerned. This is pertinent as glycosylation is required for 
stable antibodies in vivo and in inducing complement and 
antibody-dependent cellular cyotoxicity (ADCC) [47]. De-
spite differences in N-glycan structures, antibodies produced 
in plants have similar antigen-binding capacity as their ho-
mologs produced in mammalian cells. But unlike mammal-
ian cell cultures, plants are devoid of human infective viruses 
and prions [2,22]. Furthermore, an antibody half-life in the 
bloodstream as well as its ability to be recognized by Fc re-
ceptors, which are both determined by heavy chains N-
glycosylation, are not strongly affected when a plant-N-
glycan is present instead of a mammalian N-glycan [58-60]. 
Glycosylation of antibodies can be improved in plants and 
animals by transferring the genes encoding enzymes capable 
of adding N-acetylglucosamine (GlcNac), sialic acid, fucose 
and galactose to the N-glycans [47]. 
  Current limitations of plant expression systems are low 
yields of some therapeutic proteins and the impact of non-
mammalian glycosylation on the activity, immunogenicity 
and allergenicity of glycosylated plant-made pharmaceuti-
cals. The N-glycan of antibodies extracted from plants (plan-
tibodies) have been reported to not only unable to confer 
some biological properties and to induce immune response 
when tested in mice, but also may have undesirable side-
effects in patients [47]. Different strategies and new plant 
expression systems are currently being developed to improve 
the yields and quality of plant-made pharmaceuticals. The 
challenges include in choosing the transformation systems, 
adaptation of codon usage, gene silencing, design of recom-
binant transgenes with appropriate expression, tissue speci-
ficity and proper developmental regulation, and subcellular 
localization of products [22]. The location of protein accu-
mulation within the cell is important to ensure correct fold-
ing and stability of the protein [61]. Different plant organs 
(leaves, seeds, root) and plant cell compartments (endoplas-
mic reticulum, chloroplast, vacuole and oil body) have been 
used to express many therapeutic proteins [62,63]. In plants 
with large foliage volume such as tobacco, alfalfa and leg-
ume plants, expression is performed in leaves. In potato, 
corn, rapeseed, safflower, soybean, wheat or rice, protein 
accumulation is achieved in tubers or in seeds [64,65]. In 
plants, genetic material is distributed between the nucleus, 
plastids, and mitochondria. Traditionally, the production of 
transgenic plants, for basic and applied purposes, has been 
mainly through transgenes expression in the nucleus. None-
theless, there is a concern that transgenes may escape and 
contaminate the environment via pollen such as in corn [66]. 
There is now an increasing interest in expressing the trans-
genes in chloroplasts rather than the nucleus as the genes 
expressed in the plastome will not be transferred through 
pollination [66,67]. 
  Most biopharming applications target production and 
storage in seeds, which naturally accumulate high concentra-
tions of proteins and oils, and the easiest part of the plant to Cell Engineering and Molecular Pharming for Biopharmaceuticals  The Open Medicinal Chemistry Journal, 2008, Volume 2    53 
store and transport to processing facilities. Two seed-specific 
“promoters” have been used experimentally - the beta-
phaseolin promoter of common bean and the oleosin pro-
moter of Brassica species [61]. Recent advances in the con-
trol of post-translational maturations in transgenic plants will 
allow them to perform human-like maturations on recombi-
nant proteins and make plant expression systems suitable 
alternatives to animal cell factories [22]. Antibodies that 
currently cost thousands of dollars per gram might be pro-
duced in plants for $200 per gram [68]. Transgenic plants are 
expected to produce up to 10 kg antibodies per acre [69] or 1 
kg of plantibodies after 36 months. This may be achievable 
with rabbit milk, but not goat milk [58]. A plant “bioreactor” 
will allow the production of recombinant proteins up to 20 
kg/ha, regardless of the plant material considered – tobacco, 
corn, soybean or alfalfa [58]. With the whole gamut of issues 
pertaining to potential host systems for recombinant protein 
production elaborated and recognized, in the next part, new 
development and future direction of research in biopharma-
ceuticals production are discussed. 
SCIENTIFIC AND TECHNOLOGICAL INNOVA-
TIONS IN BIOPHARMACEUTICALS 
Human Stem Cells 
  The discovery that cells are capable of self-renewal has 
led to the functional definition of stem cells [70,71]. This has 
great impact in the area of targeted therapies and drug 
delivery as human stem cells may not only find application 
in the repair, regeneration and cellular replacement of dam-
aged or defective tissues, but also in the toxicological screen-
ing and discovery of new therapeutic drug molecules, and as 
a tool for in vitro investigation of cellular and developmental 
processes [72-74]. Human stem cells can be isolated, puri-
fied, expanded in number and differentiated into the cell type 
of choice in a controlled manner. The cells may be sourced 
or derived from blood and tissues postnatally (‘adult’ stem 
cells), and from the fetus (fetal stem cells) or from the blas-
tocyst in the developing embryo prior to implantation (em-
bryonic stem cells) [72,75]. Adult stem cells and progenitor 
cells found in adult tissues, act as a repair system for the 
body, replenishing specialized cells, and also maintain the 
normal turnover of regenerative organs, such as blood, skin 
or intestinal tissues. They have been used to treat 
successfully leukemia and related bone/blood cancers 
through bone marrow transplants [76]. 
  Of great interest today is in the derivation and culture of 
Human embryonic stem cells (hESC). These cells are pluri-
potent and undifferentiated, and can grow in vitro indefi-
nitely. They can potentially provide a supply of readily 
available differentiated cells and tissues of many types to be 
used for therapeutic purposes, as well as for drug screening 
and discovery [77]. The actual methods of hESC derivation 
have not changed greatly since the method first porposed 
[72,77]. It requires establishment of embryonic stem cell 
lines using the inner cell mass of an early pre-implantation 
embryo or excess human embryos from in vitro fertilization 
treatments. To enable the clinical use of hESC for cell trans-
plantation, the use of animal derived biological components 
is no longer acceptable. The main emphasis over the last 
several years has been in finding defined conditions for deri-
vation and culture of hESCs. The aim is to replace even hu-
man derived materials with completely defined systems. The 
use of embryonic stem cells is embroiled with ethical issues 
as the blastocyst may be destroyed during the process 
[72,77,78]. There are also challenges to generate cells of 
sufficient quality and quantity and to expand cell numbers 
while maintaining the fidelity of phenotype. Strategies need 
to be developed to control and direct differentiation to pro-
duce the cell type of interest in a format that is suitable for 
intended purposes [79]. 
Gene and Targeted Therapies 
  Gene therapy is a novel technique, emerge as a direct 
result of recombinant DNA revolution. Though still highly 
experimental, it has the potential to become an important 
treatment regimen as it allows the transfer of genetic infor-
mation into patient tissues and organs for the diseased genes 
to be eliminated or their normal functions rescued. The pro-
cedure allows the addition of new functions to cells, such as 
the production of immune system mediator proteins that help 
to combat cancer and other diseases [80]. The technique en-
tails stable introduction of a gene into the genetic comple-
ment of a cell, such that subsequent expression of the gene 
achieves a therapeutic goal. The desired gene can be naked 
DNA as in the case of DNA-based vaccine; or packaged into 
a vector system such as retroviruses or plasmid-containing 
liposomes, or microencapsulated, to affect gene transfer 
[2,81-83]. Once assimilated by the cells, the exogeneous 
nucleic acids must be delivered to the nucleus. The in vitro 
approach necessitates removal of the target cells such as 
blood cells, stem cells, epithelial cells, muscle cells or hepa-
tocytes from the body, cultured in vitro together with vector 
containing nucleic acid to be delivered, and the genetically 
altered cells reintroduced into the patient’s body. Another 
approach is direct administration of the nucleic-acid contain-
ing vector to the target cell, in situ in the body, such as direct 
injection of vectors into a tumour mass, or aerosol admini-
stration of vectors containing cystic fibrosis gene to respira-
tory tract epithelial cells. For intravenous injection, vector 
can be designed to be bio-specific such that it will recognize 
and bind only to the specified target cells. Selective delivery 
can be made possible by the inclusion of antibody on the 
vector surface, which specifically binds a surface antigen 
uniquely associated with the target cell; or vector engineered 
with a specific hormone that can only bind to cells display-
ing the hormone receptor [2]. The therapeutic potential of 
gene therapy includes curing in-born errors of metabolism, 
or conditions induced by the presence of a defective copy of 
a specific gene (s), including cancer, AIDS, cystic fibrosis, 
haemophilia, neurological disorder, or retinal degeneration 
[2,84-86]. 
  The antisense approach is a type of gene therapy based 
upon the generation of short, single-stranded stretches of 
DNA or RNA, termed antisense oligonucleotides, displaying 
specific nucleotide sequences. These oligonucleotides can be 
synthesized and are capable of binding to DNA at specific 
gene sites or mRNA derived from specific genes. The trans-
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mature gene protein product. This may have potential appli-
cation in treating disease states which require blocking of 
gene expression for curing effect [2]. However, antisense 
DNA technology has failed to live up to its early hype, as 
most standalone antisense companies folded [7]. The down-
fall of antisense has been attributed largely to its off-target 
effects, especially the tendency of nucleic acid sequences to 
induce generalized immune responses, as well as the diffi-
culty of delivering the therapies to the right cell types. 
  Another nucleic acid-based therapy, short interfering 
RNA (siRNAs) or microRNAs (miRNAs) or RNAi thera-
pies, have been hailed as the hallmark of new frontiers in 
biotechnology [7]. These are small noncoding RNAs that 
regulate gene expression by repressing translation of target 
cellular transcripts. Though the extent of miRNA regulation 
is not well known, increasing evidence indicates that this is a 
naturally occurring mechanism in eukaryotes, and miRNAs 
have distinct expression profiles and play crucial roles in 
numerous cellular processes. miRNAs can induce a cell to 
destroy complementary pieces of mRNA, preventing the 
target message from being transcribed. This RNA inhibition 
can be exploited to inhibit any gene of interest and may be 
particularly useful in gene therapies [2,7,87]. The major 
challenges with developing RNAi therapies also involve 
delivery to the target site, and cross-talk in signaling path-
ways. Transgene expression can be suppressed in hema-
topoietic cells using vectors that are responsive to miRNA 
regulation. A study has shown that by challenging mice with 
lentiviral vectors encoding target sequences of endogenous 
miRNAs, the efficiency of miRNAs is achieved in sharply 
segregating the gene expression among different tissues [87]. 
In another study, analysis of the relationship between 
miRNA expression levels and target mRNA suppression 
suggests that the suppression depends on a threshold miRNA 
concentration, which makes it pertinent to exploit the 
miRNA regulatory pathway and to generate vectors that 
could rapidly adjust transgene expression in response to 
changes in miRNA expression [84]. The properties of 
miRNA-regulated vectors should allow for safer and more 
effective therapeutic applications [88]. This fast target vali-
dation and easy synthesis of miRNAs are attracting attention 
from drug developers, as a potential multi-billion dollar 
therapeutic platform in the next few years [7]. 
Metabolic Engineering 
  The approaches used to improve foreign-protein produc-
tion in various expression systems include strain improve-
ment by mutagenesis and screening and genetic modifica-
tions such as the deletion of proteases from the production 
strain, the introduction of multiple copies of expressed 
genes, the use of strong promoters, gene fusions to well-
secreted proteins, the use of native signal sequences, and 
overexpression of individual endoplasmic reticulum-resident 
genes [89-92]. The basic idea is for increased productivity, 
cost reduction, and for developing new strains with more 
specific desirable characteristics such as achieving a more 
complete PTMs that could accentuate, diminish or eliminate 
the activity of the desired enzyme. This may require a more 
comprehensive analysis of the recombinant organism in 
terms of its biology, kinetics, physiology and performance. 
  Metabolic engineering takes strain improvement, from 
empirical approach through mutagenesis and selection, to a 
more directed improved productivity through the modifica-
tion of specific biochemical(s) or the introduction of new 
one(s),  via  molecular biology, physiology, bioinformatics, 
computer modeling and control engineering [9-12]. Meta-
bolic engineering comprises a synthesis step that introduces 
new pathways and genetic controls; an analysis step to eluci-
date the properties of metabolic reaction networks in their 
entirety; and the evaluation of the recombinant physiological 
state via metabolic flux determination [11]. The way and the 
speed of improving biosystems is greatly changed through 
this systems-based analysis as it involves identifying the 
reaction and/or transport bottlenecks, thermodynamic feasi-
bility, pathway flux distribution and flux control. 
  Metabolic engineering has already made impact in drug 
discovery through the synthesis of enhanced or novel natural 
products and proteins such as carotenoids, ascorbic and lac-
tic acids, xylanases, progestrones, amino acids and novel 
precursors to amino acids, biopolymers and chiral chemicals, 
extension of substrate range for growth and product forma-
tion, and the detoxification, biodegradation or mineralization 
of toxic pollutants [93]. The metabolic engineering approach 
in the precursor formation of useful stereochemistry has been 
demonstrated in the bioconversion of indene to 1-indenol 
and cis-(1S,2R)-indandiol, from which Cis-aminoindanol, a 
key chiral precursor to the HIV protease inhibitor CRIX-
IVAN, can be derived. A new operon encoding a toluene-
inducible dioxygenase (TID) discovered from Rhodococcus 
sp. I24 strain, has shown the capability of converting indene 
to 1-indenol and cis-(1S,2R)-indandiol, when the operon is 
heterologously expressed in E. coli [94]. 
Genomics, Transcriptomics, Proteomics, Metabolomics 
and Fluxomics 
  The synthesis aspect in metabolic engineering can be 
achieved if the genes to be expressed
  are available, but 
analysis is more of a problem, due to the the complexity of 
the cellular metabolism and the lack of a breakthrough tech-
nology to deal with it [11,95]. A number of powerful tech-
niques have been developed that enable a far more
 in-depth 
analysis of the cellular physiology. These include DNA se-
quencer for genomic analysis, DNA
 microarray for transcrip-
tomic analysis (simultaneous quantification
 of all gene tran-
scripts in a cell), two-dimensional gel electrophoresis, pro-
tein microarray and protein function microarray
 for proteo-
mic analysis (simultaneous quantification of a large
 number 
of proteins in a cell), gas chromatography (GC), high per-
formance liquid chromatography (HPLC), nuclear magnetic 
resonance (NMR), direct injection mass spectrometry (MS), 
or Fourier transform infrared (FT-IR) and Raman spectros-
copy for metabolomic analysis (analysis of the intracellular 
metabolite
  levels), advanced
  fermentation technology with 
on-line control and monitoring, and bioinformatics (includ-
ing mathematical
 models for analysis of pathway structures 
and control of pathway
  fluxes) [95-97]. Advances in se-
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possible to sequence the entire genomes of many organisms. 
Genomes of more than 170 microorganisms have been com-
pletely sequenced and more than 190 sequencing projects 
were active in July 2004 [98]. The completion of these se-
quencing projects coupled with rapid development of ge-
nome-derived technologies will spur the effort towards link-
ing the global gene expression analysis with cell physiology. 
Of greater impact in this effort is the development of protein 
microarrays and protein function arrays which have been 
suggested to have greater diversity of assays than DNA mi-
croarrays. A novel type of protein array has been developed 
where the recombinant proteins are bound to the surface 
without possible losses of functions. The first yeast proteome 
chip investigating protein-protein interactions and lipid-
binding; and a human proteome chip composed of 5000 pro-
teins have been reported [99]. 
  Another indispensable area in metabolic engineering for 
direct pathway modification and strain analysis is me-
tabolomics analysis. Metabolomics offers the unbiased abil-
ity to differentiate organisms or cell states based on metabo-
lite levels that may or may not produce visible pheno-
types/genotypes. To understand the global cellular functions 
at multi-controlling steps, it is imperative to carry out com-
bined analysis of transcriptome, proteome and/or me-
tabolome simultaneously [100]. In comparing two different 
strains of E. coli, it has been established through metabolic 
flux, NMR/MS and Northern blot analysis, that the glyoxy-
late shunt, the TCA cycle, and acetate uptake by acetyl-CoA 
synthetase are more active in E. coli strain BL21 than in 
JM109. This has resulted in the differences in the glucose 
metabolism and acetate excretion. Upon closer examination 
with microarrays and time course Northern blot, it is found 
that not only the glyoxylate shunt, the TCA cycle and the 
acetate uptake are different, the other metabolic pathways 
such as gluconeogenesis, anaplerotic sfcA shunt, ppc shunt, 
glycogen biosynthesis, and fatty acid degradation, are also 
active differently in the two strains [101]. 
Bioinformatics 
  The advent of bioinformatics through genome databases, 
protein databanks and other databases containing detailed 
information about biological systems has changed the land-
scape of biological and bioengineering research. This rapid 
growth of bioinformatics databases and pattern discovery 
methods provides a powerful means of achieving the goals 
of metabolic engineering. The combination of computational 
biology and expression-based analysis of large amounts of 
sequence information emerge as indispensable tools for gene 
discovery and characterization. The paradigm has changed 
from ‘vertical’ analysis of the role(s) of one or a few genes 
to ‘horizontal’ holistic approaches, studying the function of 
many or even all of the genes of an organism simultaneously 
[96]. This requirement, coupled with the rapidly increasing 
database size necessitates pattern recognition algorithm for 
association formation, feature extraction, and identifying 
homogeneous subsets of data with similar characteristics or 
dominant discriminating characteristic that can be used for 
sequence identification, function assignment or process di-
agnosis [102]. Several pattern recognition algorithms have 
emerged which has proven effective in identifying patterns 
across all data sets. These include Principal Component 
Analysis, Cluster Analysis, Mean Hypothesis Testing, multi-
resolutional scale analysis by Wavelet Transforms, Decision 
Trees, and Artificial Neural Networks. 
  Gene prediction or gene finding is the most important 
step to understand the genomic species once it has been se-
quenced [103]. The individual genes can be algorithmically 
identified from the stretches of sequence, usually genomic 
DNA; while the biochemical function of a gene can be de-
duced by comparing the DNA sequence with the sequences 
of genes of known function in the databases. A facility 
where researchers can interactively scan for recurring pat-
terns in the sequence, or investigate reading frames, variable 
regions, positions of particular codons could facilitate quick 
overview of the sequence features [104]. New computer 
tools may prove indispensable to compose genetic data at all 
levels of biological organization - from gene to population, 
species and ecosystems - for multiple purposes, including 
gene conservation. Similarly, structural genomics projects 
have begun to produce protein structures with unknown 
function. Such progress requires accurate, automated predic-
tors of protein function to be developed if all these structures 
are to be properly annotated in reasonable time. Algorithms 
that can align more than two sequences (i.e., multiple align-
ments) can help elucidate phylogenetic relationships within 
protein families, thus providing new insight into the evolu-
tion of a protein and its potential utility [105,106]. Identify-
ing the interface between two interacting proteins provides 
important clues to the function of a protein and can reduce 
the search space required by docking algorithms to predict 
the structures of complexes. An increasingly popular ma-
chine-learning approach, the support vector machine (SVM), 
has been applied for protein–protein binding sites prediction 
with high accuracy whilst avoiding over-fitting, using the 
profiles of spatially and sequentially neighbouring sequences 
and also sequence neighbours of a target residue. SVM have 
also found applications in gene expression classification, 
protein classification, protein fold recognition and prediction 
of protein solvent accessibility, -edge strands, single nu-
cleotide polymorphisms, protein secondary structure, protein 
quaternary structure and T-cell epitopes [106]. 
  Another important area is in protein–protein interfaces 
and development of methods for predicting protein interface 
residues. The side chains of the amino acids, owing to a 
large extent to their different physical properties, have char-
acteristic distributions in interior/surface regions of individ-
ual proteins and in interface/non-interface portions of protein 
surfaces that bind proteins or nucleic acids. These distribu-
tions have important structural and functional implications 
[107,108]. Interface prediction methods rely on a wide range 
of
 sequence, structural and physical attributes that distinguish
 
interface residues from non-interface surface residues. The
 
input data are manipulated into either a numerical value or
 a 
probability representing the potential for a residue to be
 in-
side a protein interface. Accurate methods have been devel-
oped for predicting the solvent accessibility of amino acids 
from a protein sequence and for predicting interface residues 
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tein [107]. Satisfactory predictions for complex-forming 
proteins that are well represented in the
 Protein Data Bank 
have been achieved, but less so for the under-represented 
ones. Efforts are reportedly being made in building
 structural 
models for multi-component structural complexes [108]. 
High Throughput Bioprocess Development 
  With greater need for rapid sampling and accurate infor-
mation on the interactions between biosystems and the bio-
process operations, microfabrication and array-based testing 
could revolutionize the drug discovery process. Miniaturized 
analytical devices could reduce reagents and sample con-
sumption, and improve the analytical speed by reducing the 
time required by running several analyses in parallel [109]. 
In combination with optical sensor technology, low-cost mi-
crobioreactor is relevant to investigate biological kinetics 
and for high-throughput evaluation of the operational or nu-
tritional parameters on cell growth and product formation in 
a systematic and statistically significant manner [110,111]. A 
multiplexed microbioreactor system with a working volume 
of 150 μl for simultaneous operation of up to eight micro-
bioreactors has been reported (Fig. 1) [112]. The reactors, 
fabricated of poly(methyl methacrylate) (PMMA) and 
poly(dimethylsiloxane) (PDMS), include miniaturized mo-
tors for magnetic stirring of the reactors, and optic sensors 
for measuring the fermentation parameters. Optical density is 
determined with a transmittance measurement through the 
reactor chamber, and in-situ measurements of dissolved oxy-
gen and pH are obtained with fluorescence lifetime sensors 
embedded in the bottom of the reactor chambers. The multi-
plexed microbioreactor system monitors and records the 
process parameters in real time for each microbioreactor. 
Parallel batch culture of E. coli fermentation data of cell 
growth, DO, and pH compare favorably with microbial fer-
mentations undertaken with the same strain and under the 
same conditions in multiple bioreactor systems at the bench 
scale. In another system, a well-mixed, 150 μl, membrane-
aerated microbioreactor run in chemostat mode reach a 
steady state condition at which E. coli cell biomass produc-
tion, substrates and the product concentrations have been 
reported to remain constant. The reactor is fed by a pressure-
driven flow of fresh medium through a microchannel. Che-
motaxisial back growth of bacterial cells into the medium 
feed channel is prevented by local heating. Using 
poly(ethylene glycol) (PEG)-grafted poly(acrylic acid) 
(PAA) copolymer films, the inner surfaces of PMMA and 
PDMS of the reactor wall are modified to generate bio-inert 
surfaces resistant to non-specific protein adsorption and cell 
adhesion. These modified surfaces effectively reduce wall 
growth of E. coli for a prolonged period of cultivation [113]. 
  An integrated array of microbioreactors has also been 
developed, leveraging on the advantages of microfluidic in-
tegration to deliver a disposable, parallel bioreactor in a sin-
gle chip, rather than on robotically multiplexing independent 
bioreactors. The system offers small scale bioreactor arrays 
with the capabilities of bench scale stirred tank reactors. The 
microbioreactor with 100 μl working volume, comprise a 
 
Fig. (1) (a) Multiplexed microbioreactor system. The ‘‘Sixfors’’ bioreactor system containing six bench-scale reactors (Infors, Switzerland). 
(b) Fermentation data obtained with the Sixfors. (c) The multiplexed system with four stirred microbioreactors and an integrated microbiore-
actor cassette. (d) Fermentation data obtained with the multiplexed microbioreactor system [112] (Reproduced by permission of The Royal 
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peristaltic oxygenating mixer and microfluidic injectors (Fig. 
2). These integrated devices are fabricated in a single chip 
and can provide a high oxygen transfer rate (kLa  0.1 s
-1) 
without introducing bubbles, and closed loop control over 
dissolved oxygen and pH (± 0.1). The system reportedly 
could support eight simultaneous E. coli fermentations to 
cell densities greater than 13 gDW/L comparable to that 
achieved in a 4 L bench scale stirred tank bioreactor. This is 
more than four times higher than cell densities previously 
achieved in microbioreactors. Bubble free oxygenation per-
mitted near real time optical density measurements could be 
used to observe subtle changes in the growth rate and infer 
changes in the state of microbial genetic networks [114]. 
Rational Drug Design 
  High-throughput screening (HTS) involves screening of 
thousands to millions of compounds to identify target or lead 
compound with useful biological activities, and accessing the 
libraries of pharmaceutical and chemical companies. Such 
technique of blind-screening of millions of compounds in the 
lab and hoping for a hit or a lead has increasingly be seen 
instead as an irrational approach. Rational drug design which 
is synonymous with structure-based design, draws the em-
phasis away from traditional random screening. It involves a 
logical, calculated approach, which may include ligand-
based approach to discovery [2,115]. It relies heavily upon 
computer modeling to modify an existing drug or design a 
new drug which will interact with selected molecular target 
important in disease progression. In silico methods are be-
coming more efficient as they allow scientists to hone in on 
and manipulate specific molecular structures of interest. A 
pre-requisite is the three dimensional structure of the drug’s 
target be known to ease the finding of the molecules that 
would interact more efficiently in an active protein site, and 
subsequently assist the chemists to design more efficient 
drugs [2,116]. Targets are normally proteins such as specific 
enzymes or receptors for hormones or ligand that would 
modify the target activity. An example being the activity of 
retroviral reverse transcriptase as an effective AIDS thera-
peutic agent. Predictive computer modeling software allows 
generation of a likely 3D structure from the amino acid pri-
mary sequence. This however must be complemented by X-
ray crystallography to determine the exact 3D structure. 
Once the 3D structure of the target protein has been resolved, 
molecular modeling software facilitates rational design such 
as a small ligand capable of fitting into a region of an en-
zyme’s active site [2]. 
  The development of combinatorial libraries, through 
techniques capable of generating large numbers of novel 
synthetic chemicals, coupled with high-throughput screening 
methods and the use of sophisticated knowledge-based ap-
proaches to drug discovery is becoming routine [2]. The dis-
covery informatics software for virtual HTS (vHTS) will 
continue to play a vital role in rational drug design [115]. It 
has been suggested that without computer modeling, identi-
 
Fig. (2). Microbioreactor array module. (a) Four reactors integrated into a single module. (b) Cross-section of a microbioreactor showing the 
peristaltic oxygenating mixer tubes and fluid reservoir with pressure chamber. (c) Top view of a microbioreactor showing optical sensors and 
layout of peristaltic oxygenating mixer and fluid injectors. Growth well is 500 mm deep, with a 100 μl working volume. (d) Cross-section 
showing the fluid injector metering valves [114] (Reproduced by permission of The Royal Society of Chemistry). 58    The Open Medicinal Chemistry Journal, 2008, Volume 2  Abdullah et al. 
fication of a potent drug would require screening of hun-
dreds of thousands of candidates, taking up to 10 years or so, 
costing hundreds of millions dollars. Computer modelling 
saves time and cost as the discovery can be made with a 
software, and fewer compounds to be prepared or modified 
to yield a highly effective drug; as compared to the cost in 
setting up an experimental HTS laboratory and developing 
assays to discover a compound [2,115]. Ironically, one of the 
major issues facing pharma and biotechs sector today is the 
lack of innovation. This downward spiral has been attributed 
among others to the heavy investment in computer-assisted 
drug design, in building chemical libraries and in high-
throughput screening at the expense of hiring innovative 
chemists and biologists [117]. There are challenges in gener-
ating high quality protein crystals to facilitate X-ray analysis, 
as NMR can only determine 3D structure of small proteins 
[2]. The crystal structure does not always accurately depict 
how a molecule will behave in vivo; and the medicinal chem-
ists also often find it difficult to develop new structures for 
the “rational” approach [116]. The “omics” technology cou-
pled with efficient and effective “knowledge and disease 
management” strategies should offer new opportunities for 
achieving rationality in drug design. In addition, much drug 
discovery and development data requires the time depend-
ence of biological responses, which means collecting the 
data at an infinite number of points, and employing time-
series methods to give a clearer understanding of biological 
processes. With this new network biology era, it becomes 
pertinent for quantitative description of all the cellular com-
munication networks and how they integrate. For these, vali-
dation of the networks through statistics to provide estimates 
of the robustness of the parameters and network structures; 
and identification and confirmation of the genetic regulation 
mechanism through fundamental genetics and biochemistry, 
are vital [116]. 
Integrated Platform 
  Current research on chemical and pharmaceutical devel-
opment and manufacturing for integrated systems focuses on 
advanced analytical and control techniques, computational 
methods for process invention and optimization and knowl-
edge management. High-throughput microscopy and imag-
ing analysis are becoming increasingly important with the 
development of fluorescence tagging, live cell experimenta-
tion, image acquisition and processing and computer soft-
ware that brings all together. In pharmacotherapy, where 
there is a greater need to observe the changes in real-time, a 
microfluidic technology has been developed for 
highthroughput live-cell screening, with fluidic control tech-
niques for kinetic studies, changes of media, changes of 
drugs or flow mixing, under microscopic scrutiny [118]. 
There is an increasing trend towards integration of in situ 
(on-line) spectroscopic measurements (particularly of reac-
tions), real-time analysis of the spectroscopic signals, and 
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feedback control to feeds, and dosing units in order to 
achieve desired reaction rates or selectivity. This is done 
with the implementation of chemometrics or multivariate 
statistical analysis for elucidating pertinent chemical infor-
mation from various process analytical measurements [118]. 
Molecular imaging has become useful for drug discovery as 
there is a greater interest in understanding the mechanisms at 
the gene and molecular level. A new technology STORM 
(sub-diffraction limit imaging by Stochastic Optical Recon-
struction Microscopy) has been developed where optical 
image is built through the orchestration of photon emissions 
of individual, switchable fluorescent molecules with molecu-
lar specificity for intracellular details. Another technique, 
MIMS (Multi-isotope Imaging Mass Spectrometry) takes 
advantage of the existence of stable non-toxic isotopes such 
as 15N. Applications include in the pulse chase, small mole-
cule drug target interaction and tracking the lineage of trans-
planted stem cells [119]. 
CONCLUSIONS 
  The ultimate aim of biopharma development is to im-
prove the quality of life and to extend longevity. The quest 
for new drugs is never ending, as is the need to understand 
disease causes beyond the symptoms. The rapid emergence 
of new technologies is revolutionizing the biopharma in-
dustry. As shown in Fig. (3), the approach in the develop-
ment of biopharmaceuticals require multi-pronged strategies. 
Promising among these are the development of molecular 
diagnostic technologies to elucidate, evaluate and monitor 
diseases, vaccine technology principally the DNA-based 
viral vaccine, and the high-throughput screening platform 
with real-time monitoring and analysis. The future for bio-
pharmaceuticals production is indeed extremely bright and 
offers an unprecedented opportunity. 
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